IL162348A0 - Platinum derivative pharmaceutical formulations - Google Patents

Platinum derivative pharmaceutical formulations

Info

Publication number: IL162348A0
Authority: IL; Israel
Prior art keywords: pharmaceutical formulations; platinum derivative; derivative pharmaceutical; platinum; formulations
Prior art date: 2001-12-06

Application number

IL16234802A

Other languages

English (en)

Original Assignee

Pharmacia Italia Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-06

Filing date

2002-11-22

Publication date

2005-11-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21744006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL162348(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-11-22 Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa

2005-11-20 Publication of IL162348A0 publication Critical patent/IL162348A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Oncology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

IL16234802A 2001-12-06 2002-11-22 Platinum derivative pharmaceutical formulations IL162348A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10/010,122 US6476068B1 (en)	2001-12-06	2001-12-06	Platinum derivative pharmaceutical formulations
PCT/EP2002/013146 WO2003047587A1 (en)	2001-12-06	2002-11-22	Platinum derivative pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
IL162348A0 true IL162348A0 (en)	2005-11-20

Family

ID=21744006

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL16234802A IL162348A0 (en)	2001-12-06	2002-11-22	Platinum derivative pharmaceutical formulations
IL162348A IL162348A (en)	2001-12-06	2004-06-03	Oxaliplatin formulations, method for stabilizing same and use thereof for preparing medicaments for treating cancer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL162348A IL162348A (en)	2001-12-06	2004-06-03	Oxaliplatin formulations, method for stabilizing same and use thereof for preparing medicaments for treating cancer

Country Status (42)

Country	Link
US (3)	US6476068B1 (sr)
EP (1)	EP1453517B1 (sr)
JP (1)	JP2005515202A (sr)
KR (1)	KR100941210B1 (sr)
CN (1)	CN100540006C (sr)
AP (1)	AP1760A (sr)
AR (1)	AR037629A1 (sr)
AT (1)	ATE317260T1 (sr)
AU (1)	AU2002352105B2 (sr)
BR (1)	BR0214757A (sr)
CA (1)	CA2468916C (sr)
CO (1)	CO5580776A2 (sr)
CR (1)	CR7362A (sr)
CY (1)	CY1105608T1 (sr)
DE (1)	DE60209145T2 (sr)
DK (1)	DK1453517T3 (sr)
EA (1)	EA008090B1 (sr)
EC (1)	ECSP045140A (sr)
ES (1)	ES2258661T3 (sr)
GE (1)	GEP20063895B (sr)
HK (1)	HK1072002A1 (sr)
HR (1)	HRP20040514A2 (sr)
HU (1)	HUP0402217A3 (sr)
IL (2)	IL162348A0 (sr)
IS (1)	IS2580B (sr)
MA (1)	MA27153A1 (sr)
ME (1)	MEP10408A (sr)
MX (1)	MXPA04005423A (sr)
MY (1)	MY134422A (sr)
NO (1)	NO330159B1 (sr)
NZ (1)	NZ533383A (sr)
OA (1)	OA12739A (sr)
PL (1)	PL206755B1 (sr)
PT (1)	PT1453517E (sr)
RO (1)	RO121509B1 (sr)
RS (1)	RS50360B (sr)
SI (1)	SI21493A (sr)
TN (1)	TNSN04104A1 (sr)
TW (1)	TW200409640A (sr)
UA (1)	UA77728C2 (sr)
WO (1)	WO2003047587A1 (sr)
ZA (1)	ZA200404525B (sr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003004505A1 (en) *	2001-07-02	2003-01-16	Debiopharm S.A.	Oxaliplatin active substance with a very low content of oxalic acid
CA2388352A1 (en) *	2002-05-31	2003-11-30	Voiceage Corporation	A method and device for frequency-selective pitch enhancement of synthesized speed
US20040022842A1 (en) *	2002-06-03	2004-02-05	Mebiopharm Co., Ltd.	Liposome preparations containing oxaliplatin
DE10314377A1 (de) *	2003-03-28	2004-10-07	Stada Arzneimittel Ag	Gebrauchsfertige Oxaliplatin-Lösungen
GB2441445B (en) *	2003-08-28	2008-04-23	Mayne Pharma Ltd	Acid containing oxaliplatin formulation
CN101703467A (zh) *	2003-08-28	2010-05-12	梅恩医药有限公司	含有酸的奥沙利铂制剂
KR101167573B1 (ko) *	2003-11-07	2012-07-30	노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드	개선된 약학적 성질을 갖는 퀴놀리논 화합물의 약학적으로허용가능한 염
US7795205B2 (en) *	2004-04-12	2010-09-14	Canyon Pharmaceuticals, Inc.	Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
CA2569739C (en) *	2004-06-09	2011-11-29	Katsuhisa Koizumi	Antitumor effect potentiator, antitumor preparation, and method for treating cancer
CA2573747A1 (en) *	2004-07-12	2006-03-02	Sicor, Inc.	Cis-diiodo-(trans-l-1,2-cyclohexanediamine) platinum (ii) complex and p rocesses for preparing high purity oxaliplatin
US20060063833A1 (en) *	2004-09-22	2006-03-23	Edgar Schridde	Ready-to-use oxaliplatin solutions
US20060063720A1 (en) *	2004-09-22	2006-03-23	Edgar Schridde	Oxaliplatin solution concentrate
DE102004052877B4 (de) *	2004-11-02	2008-06-19	Ebewe Pharma Ges.M.B.H. Nfg.Kg	Stabile wässrige Formulierungen eines Platin-Derivats
CN1311818C (zh) *	2004-11-22	2007-04-25	山东蓝金生物工程有限公司	一种抗实体肿瘤的药物组合物
DE102004063764A1 (de) *	2004-12-29	2006-07-13	Hexal Ag	Kunststoff-Flasche für Oxaliplatin
JP2006248978A (ja)	2005-03-10	2006-09-21	Mebiopharm Co Ltd	新規なリポソーム製剤
WO2006103691A1 (en) *	2005-03-28	2006-10-05	Dabur Pharma Ltd.	Stable pharmaceutical compositions of platinum (ii) antitumour agents
NZ564144A (en) *	2005-05-13	2009-11-27	Novartis Ag	Methods for treating drug resistant cancer
DE102005038347A1 (de) *	2005-08-11	2007-02-15	Hexal Ag	Herstellung einer Oxaliplatin-Lösung und Behälter sowie Behälter-Set mit der Lösung
WO2007029268A2 (en) *	2005-09-05	2007-03-15	Dabur Pharma Limited	Stable oxaliplatin formulation
CA2627544C (en) *	2005-11-29	2015-07-07	Novartis Ag	Formulations of quinolinones for the treatment of cancer
US20090076139A1 (en) *	2007-09-19	2009-03-19	Protia, Llc	Deuterium-enriched oxalplatin
US20100267824A1 (en) *	2007-11-12	2010-10-21	Intas Pharmaceuticals Limited	Stable oxaliplatin composition for parenteral administration
EP2259776A4 (en) *	2008-02-29	2011-03-16	Eagle Pharmaceuticals Inc	USEFUL TOPOTECAN SOLUTIONS
TW201021855A (en) *	2008-11-13	2010-06-16	Taigen Biotechnology Co Ltd	Lyophilization formulation
CA2774669C (en) *	2009-09-21	2017-12-19	Jw Pharmaceutical Corporation	Oxaliplatin nanoparticles and method for preparing same
WO2012006101A2 (en)	2010-06-28	2012-01-12	The General Hospital Corporation	Blood substitutes and uses thereof
CN102274171A (zh) *	2011-08-04	2011-12-14	上海希迪制药有限公司	一种奥沙利铂注射剂
US10022326B2 (en)	2012-07-18	2018-07-17	Onyx Therapeutics, Inc.	Liposomal compositions of epoxyketone-based proteasome inhibitors
JP5929607B2 (ja) *	2012-08-06	2016-06-08	ニプロ株式会社	オキサリプラチン製剤
CN102885765B (zh) *	2012-10-25	2013-11-06	哈药集团生物工程有限公司	一种盐酸伊立替康注射液及其制备方法
US10098813B2 (en) *	2014-09-03	2018-10-16	Sun Pharmaceutical Industries Limited	Perfusion dosage form
KR101683635B1 (ko) *	2014-12-29	2016-12-09	가천대학교 산학협력단	락테이트 금속염을 포함하는 암 치료용 약학 조성물
EP4011377B1 (en) *	2015-02-13	2024-10-23	Sun Pharmaceutical Industries Ltd	Intravenous infusion dosage form comprising pemetrexed
KR102293907B1 (ko) *	2015-06-30	2021-08-26	한미약품 주식회사	이리노테칸 함유 경구용 고형제제 및 그 제조방법
EP3413862B8 (en)	2016-02-09	2024-03-13	Sun Pharmaceutical Industries Ltd.	Perfusion system
WO2018087720A1 (en)	2016-11-14	2018-05-17	Novartis Ag	Compositions, methods, and therapeutic uses related to fusogenic protein minion
BR112020013111A2 (pt)	2018-01-12	2020-12-01	Metimedi Pharmaceuticals Co., Ltd.	métodos de tratamentos da doença de alzheimer, de esclerose múltipla, de pulpite, de doença inflamatória intestinal e de lesão medular
KR101998246B1 (ko)	2018-08-22	2019-07-10	주식회사 메타파인즈	금속이온에 결합된 이온화합물을 포함하는 암 치료용 약학 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6041077B2 (ja)	1976-09-06	1985-09-13	喜徳喜谷	１，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US5041578A (en) *	1988-11-22	1991-08-20	Board Of Regents, The University Of Texas System	Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents
WO1993009782A1 (en)	1991-11-15	1993-05-27	Smithkline Beecham Corporation	Combination chemotherapy
JPH0776230B2 (ja)	1992-01-13	1995-08-16	田中貴金属工業株式会社	白金化合物の製造方法
JP2673331B2 (ja)	1993-01-12	1997-11-05	田中貴金属工業株式会社	光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
JPH06287021A (ja)	1992-04-22	1994-10-11	Tanaka Kikinzoku Kogyo Kk	光学活性な白金錯化合物の光学的分割方法
WO1994012193A1 (fr)	1992-11-24	1994-06-09	Debiopharm S.A.	Combinaison de cisplatine avec l'oxaliplatine
EP0835657B1 (en) *	1992-11-27	2004-08-25	Mayne Pharma (USA) Inc.	Stable injectable paclitaxel composition
JP3025602B2 (ja)	1993-05-21	2000-03-27	デビオファームエス．アー．	光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
US5455270A (en) *	1993-08-11	1995-10-03	Bristol-Myers Squibb Co.	Stabilized solutions of platinum(II) antitumor agents
JP3547755B2 (ja)	1994-08-08	2004-07-28	デビオファーム・エス・アー	オキサリプラティヌムの医薬的に安定な製剤
ES2206478T3 (es)	1994-11-11	2004-05-16	Debiopharm S.A.	Composiciones carcinostaticas que contienen cis-oxaliplatino y otra u otras sustancias carcinostaticas compatibles.
US5919816A (en)	1994-11-14	1999-07-06	Bionumerik Pharmaceuticals, Inc.	Formulations and methods of reducing toxicity of antineoplastic agents
DE69627641T2 (de) *	1995-02-28	2004-02-05	Kidani, Yoshinori, Fujisawa	Platin(iv)-komplexe, verfahren zu ihrer herstellung und sie enthaltende carcinostatische mittel
US5776959A (en)	1995-06-05	1998-07-07	Washington University	Anticonvulsant and anxiolytic lactam and thiolactam derivatives
JP3862758B2 (ja) *	1996-03-11	2006-12-27	喜徳喜谷	二核白金錯体、その調製方法及びその錯体を含有する医薬組成物
JP3154399B2 (ja)	1996-07-04	2001-04-09	デビオファームエス．アー．	白金化合物の製造方法
DK0929293T3 (da)	1996-08-23	2004-02-02	Sequus Pharm Inc	Liposomer indeholdende en cisplatinforbindelse
US6056973A (en)	1996-10-11	2000-05-02	Sequus Pharmaceuticals, Inc.	Therapeutic liposome composition and method of preparation
NZ337502A (en)	1997-02-05	2001-02-23	Upjohn Co	Lipid complexes and liposomes of highly insoluble platinum complexes
DK1014990T3 (da)	1997-03-07	2006-12-11	Sanofi Aventis Us Llc	Antitumorkombination af 3 amino-1,2,4 benzotriazin-1,4 dioxid/paclitaxel/platin
GB9727523D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
GB9804013D0 (en) *	1998-02-25	1998-04-22	Sanofi Sa	Formulations
CA2346564C (fr)	1998-10-14	2011-05-03	Debiopharm S.A.	Conditionnement d'une preparation d'oxaliplatine
ES2206288T3 (es)	1999-08-30	2004-05-16	Debiopharm S.A.	Preparacion farmaceutica estable de oxiliplatino para su administracion por via parenteral.
WO2001066102A2 (en)	2000-03-08	2001-09-13	Bristol-Myers Squibb Company	Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
SE0003026D0 (sv) *	2000-08-25	2000-08-25	Kerstin Sunnerheim	Use for conifer sapling protection

2001
- 2001-12-06 US US10/010,122 patent/US6476068B1/en not_active Expired - Fee Related
2002
- 2002-08-22 US US10/225,607 patent/US6673805B2/en not_active Expired - Fee Related
- 2002-11-15 US US10/295,799 patent/US20030109515A1/en not_active Abandoned
- 2002-11-22 ES ES02787779T patent/ES2258661T3/es not_active Expired - Lifetime
- 2002-11-22 BR BR0214757-2A patent/BR0214757A/pt not_active IP Right Cessation
- 2002-11-22 AT AT02787779T patent/ATE317260T1/de active
- 2002-11-22 DK DK02787779T patent/DK1453517T3/da active
- 2002-11-22 IL IL16234802A patent/IL162348A0/xx unknown
- 2002-11-22 EP EP02787779A patent/EP1453517B1/en not_active Expired - Lifetime
- 2002-11-22 SI SI200220035A patent/SI21493A/sl not_active IP Right Cessation
- 2002-11-22 CN CNB028268431A patent/CN100540006C/zh not_active Expired - Fee Related
- 2002-11-22 OA OA1200400165A patent/OA12739A/en unknown
- 2002-11-22 CA CA002468916A patent/CA2468916C/en not_active Expired - Fee Related
- 2002-11-22 PL PL370254A patent/PL206755B1/pl not_active IP Right Cessation
- 2002-11-22 WO PCT/EP2002/013146 patent/WO2003047587A1/en active IP Right Grant
- 2002-11-22 MX MXPA04005423A patent/MXPA04005423A/es active IP Right Grant
- 2002-11-22 UA UA20040705324A patent/UA77728C2/uk unknown
- 2002-11-22 NZ NZ533383A patent/NZ533383A/en not_active IP Right Cessation
- 2002-11-22 RS YUP-597/04A patent/RS50360B/sr unknown
- 2002-11-22 KR KR1020047008709A patent/KR100941210B1/ko not_active IP Right Cessation
- 2002-11-22 RO ROA200400514A patent/RO121509B1/ro unknown
- 2002-11-22 GE GE5607A patent/GEP20063895B/en unknown
- 2002-11-22 PT PT02787779T patent/PT1453517E/pt unknown
- 2002-11-22 JP JP2003548842A patent/JP2005515202A/ja not_active Withdrawn
- 2002-11-22 AP APAP/P/2004/003055A patent/AP1760A/en active
- 2002-11-22 AU AU2002352105A patent/AU2002352105B2/en not_active Ceased
- 2002-11-22 DE DE60209145T patent/DE60209145T2/de not_active Expired - Lifetime
- 2002-11-22 EA EA200400777A patent/EA008090B1/ru not_active IP Right Cessation
- 2002-11-22 HU HU0402217A patent/HUP0402217A3/hu unknown
- 2002-11-22 ME MEP-104/08A patent/MEP10408A/xx unknown
- 2002-12-04 MY MYPI20024553A patent/MY134422A/en unknown
- 2002-12-04 AR ARP020104679A patent/AR037629A1/es unknown
- 2002-12-05 TW TW091135278A patent/TW200409640A/zh unknown
2004
- 2004-06-03 IL IL162348A patent/IL162348A/en not_active IP Right Cessation
- 2004-06-03 IS IS7298A patent/IS2580B/is unknown
- 2004-06-04 CR CR7362A patent/CR7362A/es not_active Application Discontinuation
- 2004-06-04 EC EC2004005140A patent/ECSP045140A/es unknown
- 2004-06-04 MA MA27715A patent/MA27153A1/fr unknown
- 2004-06-04 TN TNP2004000104A patent/TNSN04104A1/fr unknown
- 2004-06-07 CO CO04053199A patent/CO5580776A2/es not_active Application Discontinuation
- 2004-06-07 HR HR20040514A patent/HRP20040514A2/hr not_active Application Discontinuation
- 2004-06-08 ZA ZA200404525A patent/ZA200404525B/en unknown
- 2004-07-05 NO NO20042842A patent/NO330159B1/no not_active IP Right Cessation
2005
- 2005-06-08 HK HK05104822.1A patent/HK1072002A1/xx not_active IP Right Cessation
2006
- 2006-05-04 CY CY20061100574T patent/CY1105608T1/el unknown

Also Published As

Publication number	Publication date
WO2003047587A1 (en)	2003-06-12
MEP10408A (en)	2011-02-10
CN1612737A (zh)	2005-05-04
OA12739A (en)	2006-06-30
ECSP045140A (es)	2004-08-27
YU59704A (sh)	2006-08-17
DE60209145D1 (de)	2006-04-20
NO20042842L (no)	2004-07-05
NZ533383A (en)	2007-02-23
US6476068B1 (en)	2002-11-05
CA2468916A1 (en)	2003-06-12
IS7298A (is)	2004-06-03
HRP20040514A2 (en)	2004-10-31
RS50360B (sr)	2009-11-10
DE60209145T2 (de)	2006-10-26
MA27153A1 (fr)	2005-01-03
AR037629A1 (es)	2004-11-17
BR0214757A (pt)	2004-09-14
KR20050058278A (ko)	2005-06-16
RO121509B1 (ro)	2007-10-30
EA008090B1 (ru)	2007-02-27
EP1453517B1 (en)	2006-02-08
AP2004003055A0 (en)	2004-06-30
HUP0402217A2 (hu)	2005-01-28
CA2468916C (en)	2009-01-20
IL162348A (en)	2010-11-30
MXPA04005423A (es)	2004-10-11
US20030109515A1 (en)	2003-06-12
IS2580B (is)	2010-02-15
ZA200404525B (en)	2005-08-15
DK1453517T3 (da)	2006-06-19
ATE317260T1 (de)	2006-02-15
UA77728C2 (en)	2007-01-15
TNSN04104A1 (fr)	2006-06-01
AU2002352105B2 (en)	2009-12-03
EP1453517A1 (en)	2004-09-08
CO5580776A2 (es)	2005-11-30
CY1105608T1 (el)	2010-12-22
PT1453517E (pt)	2006-06-30
SI21493A (sl)	2004-12-31
EA200400777A1 (ru)	2004-12-30
ES2258661T3 (es)	2006-09-01
AP1760A (en)	2007-07-18
AU2002352105A1 (en)	2003-06-17
TW200409640A (en)	2004-06-16
CR7362A (es)	2009-02-12
KR100941210B1 (ko)	2010-02-10
CN100540006C (zh)	2009-09-16
HUP0402217A3 (en)	2005-11-28
PL370254A1 (en)	2005-05-16
NO330159B1 (no)	2011-02-28
PL206755B1 (pl)	2010-09-30
JP2005515202A (ja)	2005-05-26
GEP20063895B (en)	2006-08-10
US20030109514A1 (en)	2003-06-12
MY134422A (en)	2007-12-31
HK1072002A1 (en)	2005-08-12
US6673805B2 (en)	2004-01-06

Publication	Publication Date	Title
HK1072002A1 (en)	2005-08-12	Platinum derivative pharmaceutical formulations
GB0319041D0 (en)	2003-09-17	Pharmaceutical Formulations
HUP0302876A3 (en)	2005-05-30	Pharmaceutical formulation
IL164519A0 (en)	2005-12-18	Pharmaceutical formulations
GB0118689D0 (en)	2001-09-19	Pharmaceutical formulation
PL366432A1 (en)	2005-01-24	Pharmaceutical formulation
EP1646355A4 (en)	2012-04-18	PHARMACEUTICAL FORMULATIONS
GB0121715D0 (en)	2001-10-31	Pharmaceutical formulations
GB2392093B (en)	2006-03-08	Pharmaceutical formulations
GB2380129B (en)	2004-08-11	Pharmaceutical formulations
GB0120701D0 (en)	2001-10-17	Pharmaceutical formulations
GB0103638D0 (en)	2001-03-28	Pharmaceutical formulations
IL161306A0 (en)	2004-09-27	Pharmaceutical formulation comprising (r)-bicalutamide
GB0105560D0 (en)	2001-04-25	Pharmaceutical formulations
AU2002346457A8 (en)	2003-06-10	Pharmaceutical formulations comprising indolinone derivatives
HK1068277A1 (en)	2005-04-29	Pharmaceutical compositions comprising chelidonineor derivatives thereof
GB0124455D0 (en)	2001-12-05	Pharmaceutical formulations
GB0014851D0 (en)	2000-08-09	Novel pharmaceutical formulation
GB0014883D0 (en)	2000-08-09	Novel pharmaceutical formulation
GB0014892D0 (en)	2000-08-09	Novel pharmaceutical formulation
GB0014947D0 (en)	2000-08-09	Novel pharmaceutical formulation
GB0104749D0 (en)	2001-04-18	Pharmaceutical formulation
GB0118299D0 (en)	2001-09-19	Pharmaceutical formulations
GB0101966D0 (en)	2001-03-14	Pharmaceutical formulations
GB0014869D0 (en)	2000-08-09	Novel pharmaceutical formulation